Biotech Values

[DewDiligence]

VVUS—I’ll go out on a limb and forecast that one year post-launch, Qnexa will have less than a 40% Rx share of the combined market for Qnexa and the off-label generic constituents. (Due to branded pricing, Qnexa will have a much higher share of the dollar sales, of course.)